An audio interview that supplements the information in this article is available on AJHP's website at www.ajhpvoices.org.
P atients with cancer often receive multiple medications, 1,2 particularly during end-of-life care. 3 Polypharmacy in geriatric patients with cancer is associated with high rates of clinically relevant drug interactions (DIs), [4] [5] [6] as medications that are safe and effective when taken separately become unsafe or ineffective when taken concomitantly. 7 DI screening is critically important in oncology clinical trials for both the treatment outcomes of trial subjects and the accuracy of the research findings; undetected DIs put subjects at greater risk of toxicity or ineffective treatment and threaten the validity of comparisons between the tested treatments.
Eligibility criteria in clinical trial protocols may include warnings or restrictions against enrolling subjects taking medications that interact with the study drug. DI screening during eligibility assessment for early-phase oncology clinical trials identifies clinically relevant DIs in more than half of subjects, but the majority can be enrolled by discontinuing or changing the interacting medication, with less than 5% of subjects requiring trial exclusion due to unresolvable DIs. 8 To assist with DI screening, proto-608 AM J HEALTH-SYST PHARM | VOLUME 75 | NUMBER 10 | MAY 15, 2018 PRACTICE RESEARCH REPORTS DRUG INTERACTION SCREENING cols often include lists of interacting drugs, but the location within the protocol, comprehensiveness, and frequency of the updating of these lists are highly heterogeneous. 9 In addition, the availability of easy-to-use and up-to-date DI screening tools is scarce. An alternative approach is for pharmacists to perform DI screening within a comprehensive medication review. 10 McGahey and Weiss 11 recently proposed a standardized process for pharmacist-led DI screening for all subjects enrolling on oncology clinical trials.
The development of a standardized process for DI screening for oncology clinical trials, potentially conducted by a pharmacist, may be a worthwhile initiative. However, limited information is available on the current processes for DI screening. This lack of information was identified by SWOG (formerly known as Southwest Oncology Group), 1 of 5 federally funded clinical trials research groups constituting the National Clinical Trials Network under the aegis of the National Cancer Institute (NCI). SWOG has nearly 6,000 physician researchers at more than 950 institutions nationwide and in 6 other countries. It includes 32 NCI-designated cancer centers as well as community hospitals, private practices, and physician group networks. SWOG sites are highly diverse in their operations for prescribing, processing, and dispensing medications, including study drugs, depending on the resources available at the site. In addition, treatment may be given in an inpatient or outpatient setting, with medications administered via different routes based on patient-specific factors. The objective of this survey was to describe the current process for screening DIs within SWOG clinical trials, including the frequency of screening, the staff responsible for such screening, and the resources that are available and used to make DI decisions. Evaluation of the current process has the potential to justify the need to standardize DI assessment.
Methods
Sample selection and survey distribution. In total, there are about 950 SWOG or NCI Community Oncology Research Program sites (or institutions) that enroll subjects into SWOG clinical trials. These sites are represented by a group of 180 head clinical research associates (CRAs), each of whom is associated with multiple sites. This survey attempted to collect a single response from each of the 180 head CRAs. The response rate was calculated as the number of surveys with a single question completed of the 180 invited CRAs.
A description of the survey and a direct, though not unique, link to online survey software (Qualtrics, Provo, UT) were e-mailed to each head CRA. The e-mail invitation included instructions to complete the survey or forward it to 1 individual to complete on behalf of their sites. The instructions explained that the survey was anonymous and was not for the purposes of SWOG oversight or auditing. It was also specified that the purpose
KEY POINTS
• Pharmacist-led drug interaction (DI) screening has been recommended for all subjects enrolling in oncology clinical trials, who often have DIs due to polypharmacy.
• A survey of SWOG sites indicated that DI screening is not uniformly conducted during enrollment eligibility screening for potential oncology clinical trial subjects.
• DI screening during eligibility assessment was typically performed by clinical research coordinators or research nurses, whose knowledge and training of DIs vary.
of the survey was to understand how DI screening was being performed at SWOG sites in order to guide the potential development of a standardized system. All CRAs were requested to answer survey questions based on their actual process and not their understanding of SWOG or institutional policy. The initial invitation was sent via e-mail on October 12, 2016, with e-mail reminders sent on October 26 and November 14 of the same year. This study was determined by the University of Michigan institutional review board (IRB) to be nonregulated and as such did not require IRB approval. Participants' consent was assumed based on their willingness to complete the survey. Survey development and analysis. The survey was developed by the SWOG pharmaceutical sciences committee, composed primarily of pharmacists representing different SWOG sites. Survey topics were selected to help determine whether DI screening was occurring within SWOG clinical trials, who was performing the screening, and what resources were used during screening. One member of the committee drafted the survey questions and response options to establish the initial structure of the survey. Four members of the pharmaceutical sciences committee and 5 clinical research coordinators performed pretesting by completing the survey in Qualtrics and providing written feedback. The survey was updated based on this feedback, followed by a review of the revised survey by pharmaceutical sciences committee members to finalize questions and response options and confirm the congruency of questions with responses.
The final survey instrument, which can be obtained by contacting the corresponding author, included 10 questions and was divided into 2 main sections. The first section collected general demographic information about the individual completing the survey, the SWOG site he or she represented, and the availability of staff and resources at the site. The second
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section asked about DI screening at 2 time points: (1) during subject eligibility assessment for trial enrollment and (2) during treatment at the time of medication changes in currently enrolled study subjects. For each time point of data collection, the survey asked how frequently and by whom DI screening was performed. The final question asked about the availability of drug information resources and the frequency at which each resource was used at the institution for DI screening. The response options included a mixture of single-response, multiplechoice, "select all that apply," and grids with several options for each choice. Finally, respondents were provided an opportunity, via an open text box, to make general comments regarding the DI screening process or the challenges with DI screening at their institution. Because the objective of this study was to provide descriptive information regarding the process for DI screening for SWOG clinical trials, only descriptive analyses were performed. Textual responses to the final question were not coded for analysis but were manually reviewed by the study team.
Results
Demographics of individual and site respondents. Invitations were sent to 180 head CRAs, the survey was opened 92 times, and 83 surveys recorded a response to at least 1 question, for an overall response rate of 46.1%. At least 72 completed surveys were submitted, for a completion rate of 40.0%. The individuals completing the survey most often identified themselves as a clinical research coordinator (34%) or a research/study nurse (31%) ( Table 1) . Responding sites were most often identified as a community hospital cancer center/specialty outpatient cancer care site (52%) or an academic teaching institution/hospital (30%).
DI screening during trial eligibility. In regard to screening potential subjects for SWOG trial eligibility, a majority of sites reported that screening is "always" conducted by clinical research coordinators (65%) and research/study nurses (53%) ( Table  2) . Alternatively, the vast majority of sites (91%) reported that pharmacists are "never" responsible for enrollment eligibility screening (data not shown). Regarding screening for DIs during trial eligibility assessment, only 38% of sites reported that DI screening "always" occurs. The majority of sites (51%) reported that DI screening "only occurs if a DI is specified within the protocol exclusion criteria," while the remaining 10% of sites reported that DI screening "sometimes" occurs, and no sites reporting that it "never" occurs. The individuals performing DI screening during enrollment eligibility assessment also varied among sites; most sites reported that a clinical research coordinator (56%), research/study nurse (45%), or site principal investigator/physician (35%) performs this task, whereas only 17% of sites reported that a pharmacist is always responsible for DI screening during enrollment eligibility assessment (Table 2) .
DI screening for medication changes in study subjects. The frequency of screening DIs for enrolled study subjects who had medication changes was similar to that reported for DI screening during eligibility assessment, including 44% of sites that performed this task "only when dictated by the protocol." Most of the remaining sites reported that such screening always occurred (40%), none reported that it "never" occurred, and the remaining 16% reported that it "sometimes" occurred. DI screening for enrolled study subjects was most commonly performed by the site principal investigator/physician (59%) 
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or the research/study nurse (48%) ( Table 2) . Interestingly, pharmacists were more frequently involved in DI screening for enrolled subjects (43%) than they were during eligibility assessment (17%).
Staff and drug information resource availability and use. Every site responding to the survey reported having reliable Internet access. Greater than 90% of sites reported access to an electronic medical record (98%), clinical research associate/ study coordinator/research nurse (98%), or pharmacist (94%). Fewer sites reported access to a drug information service (73%) or drug information resources online (78%) or in textbooks (55%). When asked which resources were used for DI screening and how often, the resources most frequently cited as being used "always" included the site principal investigator (24%), a pharmacist at the practice site (23%), or the electronic medical record/clinical decision support system (21%). Fewer than 10% of sites reported that they "always" used drug information services, websites, resources, or literature searches, though many tools were used "often" or "sometimes" by more than 20% of sites. When asked about the availability and use of pharmacists as DI resources, the plurality of sites reported using pharmacists "often" (36%) or "sometimes" (29%). Twenty-three percent reported using pharmacists "always," while a small minority of sites reported that pharmacists were "rarely used" (5%), "never used but available" (4%), or "not available" (3%).
Discussion
Our survey revealed that the process and staff responsible for DI screening were highly variable across SWOG sites. A majority of sites reported that DI screening only occurred for eligibility assessment when the clinical trial protocol required it as an exclusion criterion (51%), and a plurality of sites only performed DI screening for enrolled subjects at the time of a medication change when dictated by the protocol (44%).
Contrary to recent calls for pharmacists to conduct DI screening as part of oncology trial eligibility screening, 11 only 17% of the SWOG sites in our survey reported that pharmacists always conducted DI screening during eligibility assessment. This task was most often completed by clinical research coordinators and nurses. Recent surveys of oncology nurses document a lack of familiarity with DIs for drugs commonly used in their patients 12 and a self-described need for further DI training. 13 The local principal investigator/physician was often involved in DI screening during eligibility assessment (35%) and for enrolled subjects (59%). Lack of knowledge of DIs has also been documented in surveys of prescribers, 14,15 though we are unaware of such findings for medical oncologists. Integration of clinical pharmacists into a hematology/ oncology service has been reported to enhance identification of DIs, with high rates (>97%) of acceptance of their treatment recommendations. [16] [17] [18] While such findings support the value of pharmacist involvement in DI screening, our survey found that up to 6% of SWOG sites reported not having access to pharmacists. Therefore, a standard pharmacist-conducted DI screening system within SWOG is not (22) 13 (17) Principal investigator/physician 22 (27) 27 (35) 44 (59) Staff nurse 4 (5) 4 (5) 11 (15) Pharmacist 1 (1) 13 (17) 32 (43) Other 2 (2) 2 (3) 1 (1) a Respondents were allowed to indicate more than 1 staff member per screening task. DIs = drug interactions.
b
Numerator is the number of respondents identifying a specific staff member as always (rather than sometimes or never) performing this task. Denominator is the number of respondents indicating that their site performed eligibility screening. Numerator is the (1) number of respondents identifying the same staff member as performing this task and always performing eligibility screening plus (2) number of respondents identifying a staff member as performing this task, when that staff member differed from the one performing eligibility screening. Denominator is the number of respondents reporting that their site performed DI screening at enrollment. Numerator is the number of respondents identifying a staff member as performing this task. Denominator is the number of respondents reporting that their site screened for DIs when subjects' medications were changed.
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feasible at this time, and the benefit of such a system would have to be considered within the context of its additional cost.
It may be possible to overcome the limited availability of pharmacists by integrating electronic DI screening tools that enable clinical research coordinators and research/study nurses to perform first-pass DI screening. Potential DIs identified via this platform could then be elevated to an offsite pharmacist or local principal investigator/physician for evaluation and decisions about enrollment and treatment. Several sites provided comments supporting the usefulness of electronic clinical decision support systems, and 1 indicated that it would welcome an electronic medical record system that associates patients with specific protocols and warns the provider when a potentially prohibited medication is ordered. A previous survey of oncology nurses found that 65% endorsed the usefulness of a system for detecting DIs within clinical care. 13 A prospective study of pharmacists who screened oncology patients using DI software found that previously unrecognized DIs were detected in 14% of patients, all of which led to treatment modifications. 19 Further research is needed to determine whether DI screening performed by other practitioners is similarly effective.
There are several challenges to developing and implementing a DI screening tool. Not all SWOG sites surveyed reported access to clinical decision support tools, including electronic medical records, and even fewer reported access to or the use of drug information services and resources. Concordance studies of DI checkers have found unacceptably high rates of discordance between systems, 20, 21 necessitating the development of best practices 22 and integrated informational systems [23] [24] [25] to ensure uniformity of decisionmaking. This problem is exacerbated in trials of investigational agents, for which DI information (e.g., metabolic pathway, inhibition or induction potential, mechanism of action) is not publicly available or included in standard DI software. A tool populated with protocol-specific investigational drug information for DI screening in clinical trial subjects could ameliorate these challenges.
This survey should be interpreted in the context of several limitations. The response rate (46%) was below thresholds typically used for highquality surveys (>60% and >80%), 26 creating concerns for nonresponse bias and lack of generalizability. 27 This low response rate could bias results in many ways (e.g., head CRAs at sites that did not respond were less vigilant in overseeing operations or were overworked). We attempted to minimize nonresponse rates by making the survey brief (10 questions; median completion time, 250 seconds), sending 2 follow-up invitations, and sending invitations from the SWOG operations office, which we believed would enhance survey credibility and maximize site compliance. As a consequence of this low response rate and our decision to survey head CRAs representing multiple sites instead of surveying individual sites, we did not have sufficient data to make within-study comparisons (e.g., among types of SWOG sites). An unplanned post hoc review of responses from academic teaching hospitals and community hospitals did not identify any overt differences.
Another limitation of this new survey is that it did not undergo testing of validity and reliability, and it is possible that critical questions were not asked or responses and scales were not optimal. Furthermore, survey completion via the Internet introduces the possibilities that survey invitations were not received, respondent was not the ideal person to answer questions, and multiple responses from a single institution were submitted. The survey was sent to a single head CRA representing a group of sites, with instructions to complete the survey once on behalf of the group. Therefore, responses do not actually represent single institutions, and depending on the size of the group for which a head CRA responded, the estimates reported may not accurately represent the SWOG network. Finally, the instructions explained that the survey was for use by the pharmaceutical sciences committee and was not being used by SWOG operations for oversight or auditing; however, it is possible that respondents were not completely honest out of concern that the survey was being used for oversight purposes.
Despite these limitations, this survey represents a unique data set characterizing the current practice of DI screening during SWOG clinical trials. Similar research on the frequency and process for DI screening during clinical trials is needed to determine the generalizability of our findings to non-SWOG sites that enroll subjects to NCI National Clinical Trials Network trials, sites that enroll subjects in industry oncology trials, and sites that enroll subjects to nononcology trials. Our findings indicate that pharmacists were not typically involved in DI screening during SWOG trial enrollment, which was instead conducted by research staff, including research coordinators and nurses. A system that relies exclusively on pharmacists to perform screening may not be possible, given the lack of pharmacy staff at some sites, and may be challenging based on the lack of pharmacist involvement at others. Approaches that use electronic tools optimized for use by research staff should also be considered, though challenges exist. Further research is needed to develop and test a tool to determine whether this approach could enhance the uniformity, efficiency, and effectiveness of clinical trial DI screening to ensure subject safety and accurate assessment of the benefits and harms of drugs within clinical trials.
Conclusion
A survey revealed that DI screening was not being systematically conducted within SWOG clinical trials. When DI screening did occur, it was primarily conducted by clinical research coordi-
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nators or study nurses. Pharmacist-led DI screening was not the current practice within SWOG sites surveyed and was precluded by a lack of pharmacists' availability or involvement.
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